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Placental, immune and genetic factors are thought to play an important role in preeclampia (PE)’s pathophysiology. Angiotensin-
Converting Enzyme (ACE) plays a vital role in the renin-angiotensin-system (RAS) which regulates blood pressure by converting
angiotensin I into a powerfull vasoconstrictor angiotensin II. A deletion polymorphism (D allele) has been reported to be asso-
ciated with elevated ACE activity. The aim of the this study was to investigate whether there is an association between angiotensin
converting enzyme (ACE) insertion/deletion (I/D) polymorphism and PE. In this study, 120 preeclamptic and 116 normotensive
Turkish pregnant women were genotyped for ACE I/D polymorphism and the distribution of genotype and allele frequencies of
this polymorphism in preeclampsia and controls were evaluated. Codominant, dominant and recessive models were appplied in
ACE gene I/D polymorphism. In the codominant model, DD genotype was found signiﬁcantly more frequent in preeclampsia
than controls (P = 0.016). Moreover, in dominant model (DD frequency versus DI+II frequency) there was a signiﬁcant relation
between DD genotype and preeclampsia (P = 0.006). D allele frequency was 64.6% in preeclampsia while it was 56.1% in controls
(P = 0.062). In conclusion, there was signiﬁcant diﬀerence in genotype distribution between preeclampsia and controls.
1.Introduction
Preeclampsia (PE) is a disorder that occurs in women with a
new-onset of hypertension and proteinuria after 20 weeks of
pregnancy. It plays an important role in perinatal mortality
and morbidity, as well as maternal mortality [1–8]. It aﬀects
3–5% of all pregnancies worldwide, and the best treatment
is delivery [4, 5, 9]. Although the aetiology of preeclampsia is
stillunclear,therearesomeevidencesthatpreeclampsiaisas-
sociated with abnormal placentation which is related to poor
maternal defense mechanisms and impaired placentation in
early gestation resulted from low-resistance uteroplacental
circulation [10–12].
Angiotensin-converting enzyme (ACE, EC 3.4.15.1, a
peptidyl carboxypeptidase) plays a vital role in the rennin
angiotensin system (RAS) which regulates blood pressure
by converting angiotensin I into a powerful vasoconstrictor
angiotensinII.HighACEactivitycancontributetohyperten-
sion because of its vasoconstriction eﬀect [13, 14]. An inser-
tion/deletion (I/D) polymorphism in the ACE gene occurs
due to the insertion or deletion of an Alu 289 base pairs
(bp) sequence located at intron 16 [15]. A deletion poly-
morphism (D allele) has been reported to be associated with
elevated ACE activity [16]. Some investigators have reported
in women from various geographical origins an association
between the ACE D allele or DD genotype and increased risk
of preeclampsia or pregnancy-induced hypertension [15–
19], whereas others could not [20–23]. Women included in
this study were all Caucasian.
The aim of the study was to investigate whether there is
an association between ACE intron 16 I/D polymorphisms
and PE.2 Journal of Pregnancy
Table 1: The clinical characteristics of the study population and controls.
Mean of maternal age
(years)
Mean of maternal weight
(kg)
Number of
pregnancy
Gestational age
(weeks)
Systolic blood pressure
(mmHg)
Diastolic blood pressure
(mmHg)
PE 29,00 ± 7,044 78,89 ± 10,201 2,29 ± 1,597 34,615 ± 4,698 151,56 ± 16,116 98,85 ± 12,934
Controls 27,41 ± 5,317 77,01 ± 9,985 2,27 ± 1,639 37,060 ± 4,095 110,54 ± 10,000 71,63 ± 8,044
2.MaterialsandMethods
WrittenapprovalwasobtainedfromtheEthicsCommitteeof
CukurovaUniversityHospitalandBaskentUniversity,andall
patients gave their informed consent before peripheral blood
samplesweretaken.Informationwasenrolledretrospectively
about one hundred twenty (120) preeclamptic women and
one hundred fourteen (114) normotensive women with no
history preeclampsia who delivered at two university hos-
pitals located in Adana (Cukurova and Baskent University
Hospitals) between September 2009 and August 2010. PE
cases included both severe and mild PE, and all of them were
early-onsetcases(after20weeks).Atotalof234patientswere
studied. Clinical characteristics of the study population are
reported in Table 1.
Preeclampsia was deﬁned using the criteria of the
National High Blood Pressure Education Program Working
Group: (1) increase of 30mmHg or greater of systolic blood
pressure, (2) increase of 15mmHg or greater of diastolic
blood pressure (both criteria 1 and 2 refer to before and after
20 weeks of gestation), (3) if previous blood pressure was not
known, a blood pressure must be ≥140mmHg for systolic
and ≥110mmHg for diastolic after 20 weeks of gestation,
(4) in addition to blood pressure, proteinuria was deﬁned
as the excretion of 0.3g/L (1+ on a dipstick) or greater
[24]. Women with a signiﬁcant past medical history such as
diabetes, chronic hypertension, pregnancies with malformed
fetuses or infections, twin pregnancies were excluded from
the preeclampsia patients and controls. The controls were
normotensive women who had no history of preeclampsia
and were recruited from the same centers randomly.
Maternal DNA was isolated from peripheral venous
blood leukocytes using standard salting out method as
previously described [25]. ACE intron 16 I/D polymorphism
was genotyped by 2 PCRs using 3 primers [26]. The primers
of ﬁrst PCR were 5 -CTG GAG ACC ACT CCC ATC CTT
TCT-3  and 5 -GAT GTG GCC ATC ACA TTC GTC AGA
T-3 . The 190 and 490bp products of this PCR were from D
andIalleles,respectively.Theﬁrstampliﬁcation reactionwas
carried out in a total volume of 25μL, using 200ng genomic
DNA, 25mM dNTPs, 10pmol of each primer, 1U Taq DNA
polymerase(Vivantis),and2.5μLV iB uﬀerS(Vivantis).PCR
conditions were 94◦C for 5 minutes, followed by 30 cycles at
94◦Cf o r1m i n u t e ,5 8 ◦Cf o r1m i n u t e ,7 2 ◦Cf o r2m i n u t e s ,
and a ﬁnal step at 72◦Cf o r4m i n u t e s .
To avoid the misidentiﬁcation of DI genotypes as DD, a
second PCR was performed with the same antisense primer
as in the ﬁrst and diﬀerent sense primer as 5-TTT GAG ACG
GAG TCT CGC TC-3  that generates a 408bp fragment only
in the presence of the I allele. The second PCR was carried
out in a total volume of 25μL with the same reagents of the
Table 2: Angiotensin-converting enzyme (ACE) polymorphism in
normal pregnancies and in pregnancies complicated by preeclamp-
sia (PE).
Model
Controls PE
P value n = 114 n = 120
Distribution Distribution
Codominant
DD 30 (26,3%) 52 (43,3%)
0.016 DI 68 (59,6%) 51 (42,5%)
II 16 (14,0%) 17 (14,2%)
Recessive
II 16 (14,0%) 17 (14,2%) 0.977
DD+DI 98 (86,0%) 103 (85,8%)
Dominant
DI+II 84 (73,7%) 68 (56,7%) 0.006
DD 30 (26,3%) 52 (43,3%)
Allele
D 128 (56,1%) 155 (64,6%) 0.062
I 100 (43,9%) 85 (35,4%)
ﬁrst ampliﬁcation reaction. PCR conditions were 94◦Cf o r5
minutes, followed by 40 cycles at 94◦Cf o r1m i n u t e ,6 0 ◦Cf o r
75 seconds, 72◦C for 1 minutes, and a ﬁnal step at 72◦Cf o r
10 minutes.
P C Rp r o d u c t sw e r ea n a l y s e db y2 %a g a r o s eg e la f t e r
staining by ethidium bromide. Statistical analyses were
carried out with the SPSS version 15.0. Pearson’s chi-squared
test was used for the statistical evaluation of the individual
allele and genotype frequencies. The level of statistical signi-
ﬁcance was deﬁned as P<0.05. In the ACE I/D polymor-
phism, data were analyzed under three models: a codomi-
nant, a dominant, and a recessive model.
3. Results
Theclinicalcharacteristicsofthestudypopulationareshown
in Table 1. Mean maternal age was similar between controls
and preeclampsia, while gestational age was signiﬁcantly
higher in controls than preeclampsia.
The genotype distributions and allele frequencies for
ACE I/D polymorphism were summarized in Table 2.F o r
ACE I/D polymorphism, the frequency DD genotype was
43.3%inpreeclampsia,whileitwas26.3%incontrolsanalyz-
ing data under a codominant model. In this model, the dif-
ference was found statistically signiﬁcant (P = 0.016). More-
over, in the dominant model (DD frequency versus DI+II
frequency), the diﬀerence between the two groups was foundJournal of Pregnancy 3
statistically signiﬁcant (P = 0.006). The ACE D allele fre-
quency was 64.6% in preeclampsia and 56.1% in controls,
and the diﬀerence was not found statistically diﬀerence (P =
0.062).
4. Discussion
The present study showed an association between ACE DD
genotype and preeclampsia in Turkish population. In the
analyzed Turkish population, PE cases included both severe
and mild PE and all of them were early-onset cases (after 20
weeks). On average, deliveries occurred about 3 weeks earlier
in the preeclamptic women than in the controls.
The results of previous studies on association of ACE I/D
polymorphism with preeclampsia were conﬂicting presum-
ably attributable to diﬀerences in study population, genetic
backgrounds, and size of study groups. Some studies showed
signiﬁcantlyhigherincidenceofDDgenotypeand/orDallele
in preeclampsia and/or pregnancy-induced hypertension
[15–19]. On the other hand, no diﬀerence in genotype
distribution and allele frequency and no association between
DD genotype and occurrence of preeclampsia were found in
somestudies[20–23].Apossiblereasonfortheinconsistency
among these reports may be a genetic basis that causes
diﬀerent susceptibilities among diﬀerent populations.
Inthepresentstudy,forACEI/Dpolymorphismanalysis,
we used three models: codominant, recessive, and dominant
models which were used in a study on Caucasian popu-
lation [15]. We detected diﬀerences in genotype distribu-
tion between preeclampsia and controls for the ACE gene
polymorphism when data were evaluated using a dominant
model, considering DD frequency versus DI+II and using
a codominant model. In both models, we found a higher
incidence of DD genotype in preeclampsia when compared
to controls. However, in the previous study on caucasian
population, a higher diﬀerence was found when data were
evaluated using a recessive model, considering II frequency
versus DI+DD frequency [15]. Moreover, we found no asso-
ciation between allelic frequency and preeclampsia. A weak-
ness of our study is that the data observed was obtained from
a limited population (Turkish women). The main limitation
of the study is the lack of the circulating cytokine measures
that are needed to prove a functional relationship between
polymorphisms, elevated cytokines, and PE.
In conclusion, although our results show an association
between the ACE DD genotype and preeclampsia in the ana-
lyzedTurkishpopulation,furtherstudiesusingalargernum-
ber of subjects and analyses that include genetic, environ-
mental, and other potential factors are needed to conﬁrm
these results.
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